Novartis can’t get past foul-ups at consumer plant

Novartis can't get past foul-ups at consumer plant

Novartis has recalled 4.4 million bottles of its popular Maalox products due to manufacturing problems at its troubled U.S. OTC plant that predate CEO Joseph Jimenez’s recent decision to strip the facility down to the most basic operations.

Several weeks ago, Novartis began recalling the Maalox products from the U.S. and Canada because of packaging issues. The recall encompasses 9 different types of its Maalox chewable tablets, including more than 3.4 million bottles of Maalox Advanced Maximum Strength Antacid & Antigas. According to the most recent FDA Enforcement report, the bottles may be missing a lot number or expiration date, or those identifiers may be illegible on the outer plastic bottle packaging.

A Novartis spokeswoman said in an email that “the Maalox products being recalled were manufactured at the Novartis Consumer Health manufacturing facility in Lincoln, NE, before December 2011.”


Read the source article at Pharma News